Skip to main navigation
Overview
Newsroom
News Releases
Corporate Statements
Multimedia Resources
Events & Presentations
Events
Presentations
Financials
SEC Filings
Annual Reports
Stock Information
Stock Quote & Chart
Analyst Coverage
Investor FAQs
Corporate Governance
Governance Documents
Committee Composition
Leadership
Code of Business Conduct
Corporate Responsibility
Contact the Board
Top bar
Biogen.com
Information Request
Sign up for Alerts
Search
Search
Search
SEC Filings
Form 8-K
News
Rituxan in Combination with Chemotherapy Improves Progression-Free Survival in Difficult-to-Treat Form of Blood Cancer
News
Biogen Idec to Present at the Lazard Capital Markets Fifth Annual Life Sciences Conference
News
Biogen Idec to Present at the Credit Suisse 2008 Healthcare Conference
SEC Filings
Form 4
SEC Filings
Form 4
SEC Filings
Form 4
SEC Filings
Form 4
SEC Filings
Form 4
News
Biogen Idec Elects to Participate with Genentech in the Development and Commercialization of a Next Generation Anti-CD20 Molecule
Pagination
Page 1
Next page
››
Filter by gallery
No facets
Your selection
Clear all
2008
Remove
Filter by category
Filter by category
Filter by category
Filter by category
Filter by type
Filter by tags
Filter by form group
Filter by content year
(-)
2008
(239)
Filter by content type
SEC filing
(185)
News
(54)
Tools
Print Page
Stockholder Communications
E-mail Alerts
FAQs
Facebook
Twitter
LinkedIn
Google+
